Company profile for Coda Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of neurons to treat disease. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and eng...
CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of neurons to treat disease. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and engineered receptor allow for exquisite, dose-dependent control of the neurons to generate therapeutic effect.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
151 Oyster Point Blvd, 2nd Floor South San Francisco, CA 94080
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/coda-biotherapeutics-announces-new-preclinical-data-from-epilepsy-program-showing-significant-correlation-between-gene-expression-and-efficacy-301558686.html

PRNEWSWIRE
01 Jun 2022

https://www.prnewswire.com/news-releases/coda-biotherapeutics-names-susan-catalano-phd-as-chief-scientific-officer-301496990.html

PRNEWSWIRE
08 Mar 2022

https://www.prnewswire.com/news-releases/coda-biotherapeutics-chemogenetic-gene-therapy-platform-can-control-focal-seizures-in-vivo-301438518.html

PRNEWSWIRE
07 Dec 2021

https://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

PRNEWSWIRE
10 Nov 2020

https://www.prnewswire.com/news-releases/coda-biotherapeutics-announces-research-collaboration-with-the-facial-pain-research-foundation-301061101.html

PRNEWSWIRE
20 May 2020

https://www.prnewswire.com/news-releases/coda-biotherapeutics-acquires-attenua-and-three-clinical-stage-assets-300999026.html

PR NEWSWIRE
05 Feb 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty